POLICY NAME | Agency |
---|
...
(ONC/FDA/etc) | ||
---|---|---|
Docket# | Type: RF. So published request | |
Date: Comments must be received before 1/1/ |
...
202, midnight, EST | Method: Comments should be submitted through the federal register |
...
/other: Link | ||
Summary: | ||
Paragraph or two summary or |
...
Two
(or more? - brooke, how long?)
Potential main points +/- questions under each if relevant
1 paragraph and 5-7 bullets | ||
PHA/PHL- identified impacts: | ||
| ||
Top 5 areas of requested feedback from PHA/Ls, partners, etc: | ||
| ||
Thing 1 | search for ‘section 4.2’ | |
| ||
Thing 2 | search for ‘public health reporting’ - multiple places | |
| ||
Thing 3 | search for ‘data reporting standards’ and look at the cluster about halfway through policy | |
| ||
Thing 4 | search for ‘green ceiling’ | |
| ||
Thing 5 | search for early ‘definitions’ section, then ‘urgent’ term | |
| ||
Additional potential impacts or language of interest | ||
|
| maybe |
Additional space for notes or additional comments or etc from partners: | ||
Should we request an extension of comment period? | ||
HL7 has asked us to provide input on how requiring FHIR ELR messaging in 2025 would impact PHA pre-processing, reporting, and PHL LIMs projects. |